If you are living with kidney disease or may be at risk due to APOL1 gene variants, you may qualify for a clinical research study evaluating a potential new treatment.
What to Expect
Participants in the APPRECIATE Study will receive:
Free APOL1 genetic testing to determine eligibility
A weekly at-home injection of a study drug or placebo
Care and oversight from a team of experienced kidney specialists
Routine lab tests and health assessments to monitor kidney function
The opportunity to take part in an extension study if the drug shows promise
Compensation may be provided for time and participation
All study-related visits, testing, and care are provided at no cost to you.
Trial Requirements
- Between 18 and 75 years old
- Have been diagnosed with, or are at risk for, APOL1-mediated kidney disease (AMKD)
- Carry two copies of the APOL1 gene variants (G1/G1, G1/G2, or G2/G2)
- Are not pregnant, breastfeeding, or planning to become pregnant during the study
Urgently Recruiting
Trial Details
This Study is testing an investigational drug called AZD2373, designed to lower harmful APOL1 protein levels in the body—without altering DNA. This may help protect kidney function in people with genetic risk.
